poisar

Stocks · News reference

Argus Research Maintains Buy on CVS Health, Raises Price Target to $114

BenzingaAug 19, 2026, 1:25 PMBenzinga Newsdesk

Argus Research analyst Steve Silver maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $104 to $114.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 19, 2026, 1:25 PM
Checked
Aug 19, 2026, 1:25 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARAug 17, 2026, 8:19 PMSEC EDGAR

    8-K filing — CVS HEALTH Corp (CVS)

    Filed: 2026-08-17 AccNo: 0001193125-26-354096 Size: 159 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    Read original at edgar